Prostate artery embolization (PAE) was not recommended for inclusion in benefit catalogue in patients with benign prostatic hyperplasia in Austria


Aug 2017

There are four embolization agents used for prostate artery embolization (PAE) that have received marketing authorization in the European Union:

  • Embozene™ Microspheres (Boston Scientific, USA)
  • Bead Block® polyvinyl alcohol hydrogel (Biocompatibles UK Ltd, UK)
  • Embosphere® trisacryl microspheres (Merit Medical Systems Inc., USA),
  • PVA Foam Embolisation Particles (Cook Medical, USA)

Currently, PAE is not included in the Austrian hospital benefit catalogue, and therefore is not reimbursed by the Austrian health care system.

In 2017, PAE was evaluated by the Ludwig Boltzmann Institute – Health Technology Assessment (LBI-HTA) to define whether this minimally invasive procedure can be sufficient for inclusion into benefit catalogue. Within this research work, evidence in relation to efficacy and safety of PAE were assessed in comparison to transurethral resection of the prostate (TURP) and open prostatectomy. Two RCTs comparing PAE to TURP (n = 144), and one matched-pairs study comparing PAE to open prostatectomy (n = 160), were identified for evaluation of effectiveness outcomes. Additionally, one RCT comparing PAE particle sizes, two non-randomized studies comparing different populations treated with PAE, and two single-arm studies of PAE were included for evaluation of safety outcomes.

A strength of evidence for comparison PAE with TURP and open prostatectomy in relation to effectiveness was low. The same situation with evidence for safety where a strength of available evidence was assessed as very low, low and moderate. Based on these findings LBI-HTA does not currently recommend PAE for inclusion into benefit catalogue in Austria.

However, there is potential evidence that might improve recommendations for the procedure that are based on ongoing studies:

  • Five ongoing studies that have the aim to compare PAE to TURP in patients with moderate-to-severe LUTS, which are currently scheduled for completion before the 2021 year:
    • Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia (NCT02054013, n=101, completion date – December 2022)
    • Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia (NCT01789840, n=186, completion date – May 2018)
    • Prospective Controlled Randomized Study of PAE vs TURP for BPH Treatment (NCT02566551, n=100, date of completion – May 2018)
    • Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms (NCT01963312, n=81, completion date - November 2018)
    • Prospective randomized interventional single-center study to evaluate preoperative transarterial embolization of the prostate before prostatectomy (DRKS00008079, n=100; completion date – not known)
  • One RCT of comparison of PAE with medical therapy
    • Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia (PARTEM) (NCT02869971, n=90, completion date – February 2021)
  • One RCT compared PAE to sham procedure (NCT02074644, n=80, completion date – December 2018)
  • Two patient registries compared PAE to TURP and open prostatectomy
    • ROPE Registry Project to Determine the Safety and Efficacy of Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement (LUTS BPE). (UKROPE) (NCT02849522, n=300, completion date – September, 2017)
    • UK ROPE Register Study (UK ROPE) (NCT02434575, n=300, completion date – December, 2017)
  • Additionally, several non-comparative observational studies for assessment of PAE is planned to be completed until 2021 year

Thus, LBI-HTA recommended re-evaluating PAE procedure in the 2021 year when new potential evidence is available.

See full report here.

Subscribe to our newsletter delivered every second week not to miss relevant reimbursement information.

The latest related news


Nov 2022

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 21738 of November 4, 2022, Tuscany Regional Healthcare has published assessments of three medical devices in the orthopedics, surgical procedures, and peripheral vascular areas.

Read more


Nov 2022

On October 28, 2022, several Resolutions of the General Directorate of the Common Package of Benefits of the National Health and Pharmacy System were published concerning the use of the system for percutaneous repair of the mitral valve with clip, prioritization of patients with type 2 diabetes mellitus for the provision of glucose monitoring systems, and the use of glucose monitoring system with sensors (flash type) for type 1 diabetes mellitus in childhood and adolescence.

Read more


Nov 2022

MedTech-related health technology assessments from NIHR in October 2022
In October 2022, the National Institute for Health and Care Research (NIHR) in England released one MedTech-related report in its Health Technology Assessment (HTA) Journal, which concerned photodynamic versus white-light-guided resection of non-muscle-invasive bladder cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more


Nov 2022

On October 31, 2022, the Dental and Pharmaceutical Benefits Agency (TLV) initiated conducting a theme survey for technologies used for the diagnosis or treatment of lung or colorectal cancer. Manufacturers of medical devices have an opportunity to notify TLV about a new product related to the theme of the survey. The notification form is available on the TLV website and should be submitted no later than November 22, 2022.

Read more


Nov 2022

In October 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (YAG laser vitreolysis for symptomatic vitreous floaters, transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine), one Medical Technologies Guidance (Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer) and three new Medtech Innovation Briefings (O2matic PRO 100, Daylight, Signatera). Also, one new clinical guideline was published on osteoarthritis.

Read more